Chondrosarcoma is notable for its lack of response to conventional cytotoxic chemotherapy, propensity for developing lung metastases, and poor survival. Therefore, a better understanding of angiogenic and metastatic pathways is needed. Multiple pathways regulate angiogenesis and metastasis, including chemokines and their receptors.
Introduction
Chondrosarcoma is a devastating disease without effective systemic treatment. It is the second most common primary malignant bone tumor in large epidemiologic series (1) .
Five-year survival of patients with this cancer is 10% to 25% and there has been no progress over the last several decades (2;3). The consensus is that conventional cytotoxic chemotherapy does not improve survival (4) . Patients with chondrosarcoma typically succumb to pulmonary metastases. Angiogenesis is necessary for both tumor growth and metastasis (5;6) . Virtually all of the research on tumor vascularity and the factors that stimulate angiogenesis have shown correlations between vascularity, expression of proangiogenic factors, biologic aggressiveness, high pathologic grade, and poor survival (7) . We found grade II and III chondrosarcomas have more microvascularity than benign or grade I tumors (8) . Microvascularity correlates with clinical behavior, since it is primarily grade II and III chondrosarcomas that metastasize (9). Thus, chondrosarcoma development may be linked to angiogenesis.
The angiogenic switch typically involves hypoxia and oncogenes as activators of expression of the primary proangiogenic factor VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGFA) (6) . We have shown grade II and III chondrosarcoma have higher expression of VEGFA and the major transcription factor related to hypoxia, HYPOXIA-INDUCING FACTOR 1 (HIF1) (10) . In addition to VEGFA, MATRIX METALLOPEPTIDASES (MMPs) are factors related to angiogenesis and metastatic behavior and MMP1 expression in chondrosarcoma is inversely correlated with survival (11) . Directly blocking expression of these factors in vivo is not yet feasible and our understanding of the regulation of these factors in chondrosarcoma is incomplete. Under normal circumstances they are important in immune cell function and migration of stem cells to sites of injury; however, in cancer, they regulate invasion, angiogenesis, migration, and metastasis. CHEMOKINE (C-X-C MOTIF) RECEPTOR 4 (CXCR4) is the chemokine receptor most commonly expressed in tumors (12) . The ligand for CXCR4 is CHEMOKINE (C-X-C MOTIF) LIGAND 12 (CXCL12) (13;14) . CXCR4 and CXCL12 together promote metastasis in some tumors by mediating proliferation and migration of tumor cells and enhancing tumor-associated angiogenesis (15) (16) (17) . CXCR4 is a transmembrane G-protein-coupled receptor, whose activation also leads to intracellular signaling cascades, downstream targets of which include MMP1 and VEGFA (17;18). The increased expression of chemokine receptors has been mostly investigated in carcinomas (19-22). We (23) and others (24) have found CXCR4 is overexpressed in chondrosarcoma cells and primary chondrosarcoma tissue, and we have also shown that one mechanism of increased CXCR4 expression is hypoxia, specifically HIF1(23). VEGFA has also been shown to upregulate CXCR4 expression in endothelial cells, and in some, but not all tumor cells (25;26). Development of agents that block CXCR4 has been propelled by the fact that it is a coreceptor for HIV. The drug AMD3100 is a bicyclam (1,1'-[1,4-Phenylenebis-(methylene)]-bis-(1,4,8,11-tetraazacyclotetradecane) octahydrochloride) (27) with high specificity for CXCR4 and is the prototypical CXCR4-blocking drug (28) . It is already approved for human use as a stem cell mobilizer. In chondrosarcoma cells, CXCR4 blockade with AMD3100 inhibits expression of MMP1 and invasion in vitro (23). CXCR4, therefore, is an attractive target MCT-12-1092 since it is the most common chemokine receptor expressed in cancer cells, upregulates factors related to invasiveness and angiogenesis in chondrosarcoma, and agents exist that can block this receptor. As an orphan disease, it is unlikely that novel agents will be developed for chondrosarcoma and repurposing the use of drugs approved for one use to the treatment of orphan diseases is an NIH priority (29) . Thus, it is important to identify pathways and agents that may have applicability for chondrosarcoma treatment.
In this study, we (1) investigated another potential mechanism of CXCR4 overexpression in chondrosarcoma involving the mutual regulation of VEGFA and CXCR4 by each other, (2) tested the hypothesis that CXCR4 inhibition decreases VEGFA expression and angiogenesis in vitro and in vivo, and (3) tested the hypothesis that CXCR4 inhibition decreases metastasis.
Material and Methods

Chondrosarcoma cell line
The human chondrosarcoma cell line JJ, derived from a human Grade II chondrosarcoma 
Quantitative real-time PCR analysis for mRNAs
For quantification of mRNA, total RNA was isolated from chondrocytes, JJ cells, and xenograft mouse tumors using the RNAqueous ® Kit (Ambion, Austin, TX, USA). SYBR real-time PCR was carried out using two-step real-time qRT-PCR (Qiagen) with normalization to 18S rRNA (18S). The primers used for VEGFA, CXCR4, and 18S
were previously reported (23;31). 18S was used as an internal control since it is reportedly the optimal reference gene (32) . The comparative threshold cycle (Ct) method, i.e., the 2 -∆∆Ct method, was used for the calculation of fold amplification (33) .
Each experiment was evaluated with three PCR reactions and each experiment was repeated three times, the sample size necessary to maintain power at 0.80 to detect a 50% decrease with an alpha of 0.025 (one-tailed t-test).
Western Blot
Cell lysates containing forty µg of protein were separated via SDS-PAGE (Bio-Rad, Hercules, CA). Western Blot analyses were performed as previously described with CXCR4 antibody (IMGNEX, San Diego, CA) and actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) (34) . Protein concentrations were determined using the Quick Start Bradford protein assay (Bio-Rad). 
Statistical analysis
Gene expression in multiple groups in vitro were compared using one-way ANOVA, followed by Bonferroni's multiple comparison test. We determined differences in gene and protein expression in vivo, bioimaging, and tumor weight and volume between control and AMD3100 or CXCR4siRNA groups using Student's t-test. Lung metastatic burden was compared using Mann-Whitney U test. (GraphPadPrism, v 5.03, GraphPad Software, Inc., San Diego, CA).
Results
While it is known that CXCR4 is upregulated in primary human chondrosarcoma, we evaluated CXCR4 expression in xenograft tumors to confirm the model could be used to study CXCR4 inhibition. CXCR4 was expressed at higher levels in JJ cells compared to normal chondrocytes, and expression was further increased (p < 0.001) by hypoxia 46-fold and in xenograft tumors 438-fold, both relative to chondrocytes. Western blot confirmed the results (Fig.1) , suggesting CXCR4 may be a relevant treatment target. (Fig. 2A) . Similarly, CXCR4 mRNA increased fivefold (p < 0.02) after cells were treated with VEGFA (Fig. 2B) . CXCL12 treatment during hypoxia increased VEGFA protein concentration in conditioned media ( Figure 3A) , HUVEC tube formation (Figure 3b) , and the effects were attenuated by AMD3100.
The effect of CXCR4 siRNA on VEGFA mRNA and protein expression and HUVEC tube formation were similar to treatment with AMD3100, suggesting the effects of AMD3100 result from inhibition of CXCR4 signaling. CXCR4 siRNA efficiently knocked down CXCR4 expression (90% knockdown of mRNA) (Fig 4A, B) , decreased VEGFA mRNA by 68% (Fig. 4A , p < 0.01), and VEGFA protein in conditioned medium by 51% (Fig. 4C , p < 0.02). Conditioned medium from JJ cells cultured in hypoxia after CXCR4 knockdown had 35% less effect on formation of HUVEC tube length (Fig. 4D, (Fig. 5A-B) . VEGFA content in treated tumors was decreased 45% of control (p < 0.002) (Fig. 5C ). Representative immunohistochemical staining shows less CD31-positive microvessels within treated tumors (Fig. 5D ). Final tumor weight and volume were decreased by 44% and 45% respectively (Fig. 6A,B) (p< 0.05). Evaluation of lungs demonstrated that AMD3100 treatment decreased the number of lung nodules by 56% (Fig. 6C) (p < 0.04). Chondrosarcoma is notable for its lack of response to systemic treatment and poor survival. Chemokines and their receptors regulate invasion, angiogenesis, migration, and metastasis. CXCR4 is the most common chemokine receptor expressed in cancer cells and upregulates factors related to invasiveness and angiogenesis. We therefore determined whether CXCR4 signaling contributes to VEGFA expression in chondrosarcoma and whether blocking CXCR4 would inhibit angiogenesis and metastasis in this tumor.
Regulation of VEGFA expression in chondrosarcoma, as in other tumors, involves a physiologic response to hypoxia and genetic aberrations found in tumors, with some overlap. VEGFA is directly upregulated by the transcription factor HIF1, which is increased during hypoxia as a result of decreased degradation (31). Here we show VEGFA is also upregulated by CXCR4 signaling in a positive feedback loop. The mechanisms of CXCR4 signaling include the MAP kinases ERK, JNK, and p38(36), which are known to upregulate VEGFA promoter activity (37) . CXCR4 has been previously reported to be upregulated by VEGFA in normal endothelial cells and in breast cancer (26), however this is the first report of such upregulation in chondrosarcoma. CXCR4 is also upregulated by hypoxia via HIF1 (23). Therefore, there are multiple levels of regulation and amplification of VEGFA and CXCR4 expression.
VEGFA expression is directly regulated by HIF1, which binds to the VEGFA promoter, and indirectly by CXCR4 signaling, which itself is increased by HIF1, VEGFA, and other factors such as PEA3, PAUF, PAX3-FKHR, nuclear respiratory factor 1, and estrogen antibody, upregulated CXCL12 and CXCR4 in tumors and plasma CXCL12 levels, which correlated with development of lung metastases. This suggests anti-VEGF monotherapy can be accompanied by compensatory mechanisms and blocking CXCR4 in addition to VEGFA will be important in combination therapy (47) . There is also the notion that normalization of tumor vasculature with anti-VEGF treatment will increase the efficacy of conventional cytotoxic chemotherapy (48). AMD3100 is a drug approved for human use as a stem cell mobilizer whose mechanism of action is specific inhibition of CXCR4. The extent to which CXCR4 inhibition with AMD3100 or other molecules alone or as part of combination therapy as treatment for chondrosarcoma in humans needs to be evaluated.
In summary, our results show that VEGFA expression increases CXCR4 expression and that CXCR4 blockade inhibits VEGFA production, angiogenesis, and metastasis in vitro and in a mouse chondrosarcoma xenograft model. 
